ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

IM Naltrexone Post Liver Transplant for Alcoholic Hepatitis Patients to Prevent Relapse

A. Flecha

Transplant Surgery, Montefiore Medical Center, Bronx, NY

Meeting: 2020 American Transplant Congress

Abstract number: B-174

Keywords: Alcohol, Ethics, Hepatitis, Liver

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session B: Liver: Recipient Selection

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • U.S. Outcomes in Early Liver Transplantation for Alcoholic Hepatitis: Results from the American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH).
  • Higher Early Post-Liver Transplant Mortality in Recipients with Severe Alcoholic Hepatitis versus Alcoholic Cirrhosis

*Purpose: The number of patients requiring liver transplants due to Hepatitis C Virus is declining due to the new treatment options, and the growing number of adult patients requiring liver transplantation are alcoholic hepatitis and cirrhsosis. This population is often a difficult one to transplant, depending on the amount of time they have abstinent from alcohol, some having no time and needing a transplant immediately, or they will die.

*Methods: At Montefiore we decide as a Multidisciplinary Team if a patient is a candidate for a solid organ liver transplant. We recently initiated IM Naltrexone 380 mg monthly administered in our clinic, to our alcoholic hepatitis/cirrhotic patients post transplant to aide in prevention of relpase. In the immediate post operative period patients cannot enroll in inpatient rehabilitation due to frequent doctor visits and hospital readmissions. In this critical time pharmaceutical treatment can greatly aide in abstinence along with therapy.

*Results: We have enrolled 10 patients in our Naltrexone Im post liver transplant for alcholic hepatitis/cirrhosis if they had either less than 6 months of abstinence. Of those 10 patients 3 relapses and 2 were able to again abstain and 1 is still drinking. We added 1 patient post tarnsplant who had been drinking and stopped once pharmacotherpay was initiated. Of all of our alcoholic patients we transplanted we estimated ~ 50% have drank post transplant without pharmacologic intervention.

*Conclusions: By adding a pharmacologic intervention, in this case monthly IM injections of 380 mg of IM naltrexone we were able to decrease our patients rates of relapse from 50% to 30%. This should be considered as a new standard of care for patients transplanted for alcoholic heptatitis/cirrhosis with less than 6 months of sobriety or if they relpase after transplant.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Flecha A. IM Naltrexone Post Liver Transplant for Alcoholic Hepatitis Patients to Prevent Relapse [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/im-naltrexone-post-liver-transplant-for-alcoholic-hepatitis-patients-to-prevent-relapse/. Accessed April 18, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.